~15 spots leftby Dec 2026

Sacituzumab Govitecan + Nivolumab for Bladder Cancer

Recruiting in Palo Alto (17 mi)
UC Irvine - Faculty Profile System
Overseen byNataliya Mar, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Recruiting
Sponsor: University of California, Irvine
Must not be taking: Immunosuppressants, Corticosteroids
Disqualifiers: Autoimmune disease, Active malignancy, others
Stay on Your Current Meds
No Placebo Group
Prior Safety Data
Breakthrough Therapy

Trial Summary

What is the purpose of this trial?

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.

Will I have to stop taking my current medications?

The trial protocol does not specify if you need to stop taking your current medications. However, if you are on high-dose corticosteroids or other immunosuppressive medications, you may need to stop them 14 days before starting the study treatment.

What data supports the effectiveness of the drug Sacituzumab Govitecan for bladder cancer?

Sacituzumab govitecan has shown preliminary activity in patients with metastatic urothelial carcinoma (a type of bladder cancer) who have limited treatment options after other therapies. It is an antibody-drug conjugate that targets a protein called Trop-2, which is often found in high amounts in these cancers.12345

What safety information is available for Sacituzumab Govitecan in humans?

Sacituzumab Govitecan has been associated with side effects like neutropenia (low white blood cell count), diarrhea, colitis (inflammation of the colon), and sepsis (a severe infection). These side effects often occur within 30 days of starting treatment, and some can lead to hospitalization, especially in males.23467

How is the drug Sacituzumab Govitecan + Nivolumab unique for bladder cancer?

Sacituzumab Govitecan is unique because it is an antibody-drug conjugate that targets Trop-2, a protein found in many cancers, and delivers a chemotherapy agent directly to cancer cells. This approach is different from traditional chemotherapy as it aims to reduce side effects by specifically targeting cancer cells. Nivolumab, on the other hand, is an immunotherapy that helps the immune system recognize and attack cancer cells, making this combination a novel approach for treating bladder cancer.12368

Research Team

UC Irvine - Faculty Profile System

Nataliya Mar, MD

Principal Investigator

Chao Family Comprehensive Cancer Center

Eligibility Criteria

This trial is for individuals with muscle-invasive urothelial carcinoma, which includes cancers of the bladder, ureter, or upper tract. It's specifically for those at high risk of cancer coming back after surgery meant to cure them.

Inclusion Criteria

I am 18 years old or older.
My cancer started in the bladder, ureter, or renal pelvis and is not small cell carcinoma.
Radiographic disease-free status as determined by imaging within 28 days of C1 D1 of study treatment
See 9 more

Exclusion Criteria

I haven't had any cancer except for certain types in the last 3 years.
I have or might have an autoimmune disease.
I have had radiation therapy for urinary cancer.
See 12 more

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive combination therapy with Sacituzumab Govitecan and Nivolumab for 4 cycles, followed by single-agent Nivolumab for an additional 11 cycles

15 cycles

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 5 years

Treatment Details

Interventions

  • Nivolumab (Monoclonal Antibodies)
  • Sacituzumab Govitecan (Monoclonlonal Antibodies)
Trial OverviewThe study is testing a combination therapy using two drugs: Sacituzumab Govitecan and Nivolumab. As it's a phase 2 single-arm study, all participants will receive this combo treatment to see how effective it is in preventing cancer recurrence.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Sacituzumab Govitecan PLUS NivolumabExperimental Treatment2 Interventions
Patients eligible for this study treatment will receive combination therapy with Sacituzumab Govitecan with Nivolumab for 4 cycles, followed by single-agent Nivolumab for an additional 11 cycles.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Irvine

Lead Sponsor

Trials
580
Recruited
4,943,000+
Chad T. Lefteris profile image

Chad T. Lefteris

University of California, Irvine

Chief Executive Officer since 2019

MBA from University of California, Irvine

Michael J. Stamos profile image

Michael J. Stamos

University of California, Irvine

Chief Medical Officer since 2019

MD, PhD from University of California, Irvine

Gilead Sciences

Industry Sponsor

Trials
1,150
Recruited
878,000+
Daniel O'Day profile image

Daniel O'Day

Gilead Sciences

Chief Executive Officer since 2019

MBA from Columbia University

Dietmar Berger profile image

Dietmar Berger

Gilead Sciences

Chief Medical Officer

MD and PhD from Albert-Ludwigs University School of Medicine

Findings from Research

Sacituzumab govitecan (SG) is an effective treatment for locally advanced and metastatic urothelial cancer, showing a 27% objective response rate in the TROPHY-U-01 phase II trial.
While SG has common side effects like diarrhea and neutropenia, these can be managed with supportive care, and it has received accelerated approval for patients who have previously undergone platinum-based chemotherapy and PD-1 or PD-L1 inhibitor treatments.
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma.Mathew Thomas, V., Tripathi, N., Agarwal, N., et al.[2022]
In a phase I trial involving 23 patients with metastatic urothelial carcinoma, the combination of sacituzumab govitecan (SG) and enfortumab vedotin (EV) demonstrated a high objective response rate of 70%, with three patients achieving complete responses.
The study identified a safe dose for further testing, with 78% of patients experiencing grade ≥3 adverse events, indicating that while the treatment is effective, careful monitoring for side effects is necessary.
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.McGregor, BA., Sonpavde, GP., Kwak, L., et al.[2023]
Enfortumab vedotin and sacituzumab govitecan are novel antibody-drug conjugates that improve treatment options for patients with advanced bladder cancer after they have received platinum-based therapy and immune checkpoint inhibitors, with enfortumab vedotin showing improved overall survival.
Sacituzumab govitecan has a 27% response rate in treating advanced bladder cancer, highlighting its potential effectiveness, but careful consideration of the safety profiles of both agents is essential for optimizing patient outcomes.
The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer.Hanna, KS., Larson, S., Nguyen, J., et al.[2022]

References

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. [2022]
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. [2022]
Sacituzumab Govitecan: First Approval. [2021]
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma. [2023]
The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer. [2022]
Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer. [2021]
Postmarketing safety of Sacituzumab govitecan: a pharmacovigilance study based on FDA adverse event reporting system (FAERS). [2023]
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors. [2022]